BIO, PhRMA Oppose Granting FDA Authority To Mandate Postmarket Studies
The Pharmaceutical Research & Manufacturers of America and the Biotechnology Industry Organization oppose granting FDA the power to require postmarketing studies
You may also be interested in...
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act
Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said